GSK to Partner with Ionis For Hep B Drug Development
GSK will handle the development, regulatory, commercialization activities, and costs of the drug, while Ionis will obtain license fees and milestone payments of up to $262 million, including a $25 million license fee.
GlaxoSmithKline (GSK) has exercised its option to license antisense medicines from Ionis Pharmaceuticals, an RNA-targeted therapeutics company based in Carlsbad, CA, for people with chronic hepatitis B virus (CHB) infection following positive Phase II results, Ionis announced on Aug. 27, 2019.
Ionis will now be eligible to obtain license fees and milestone payments of up to $262 million, including a $25 million license fee, along with tiered royalties in the low double digits on net sales, according to a company press release. GSK will be responsible for development, regulatory, commercialization activities, and costs of the drug.
"By targeting the root cause of CHB-related liver disease, our antisense technology can potentially deliver a transformative medicine for people who suffer from chronic hepatitis B virus infection," said Brett P. Monia, chief operating officer at Ionis, in the press release. "We believe GSK's development and commercialization expertise in infectious diseases makes them the ideal partner to help address this high unmet need."
Source: Ionis Pharmaceuticals
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
